H.C. Wainwright Reiterates Buy Rating on Palvella Therapeutics (PVLA)

February 11, 2025 6:47 AM EST Send to a Friend
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $38.00 price target on Palvella Therapeutics (NASDAQ: PVLA).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login